Log in

Relevant bibliographies by topics / Antileukemic / Journal articles

To see the other types of publications on this topic, follow the link: Antileukemic.

Journal articles on the topic 'Antileukemic'

Author: Grafiati

Published: 9 March 2023

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Antileukemic.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Kakar, Satinder, Anurekha Jain, and Ramandeep Singh. "In vivo study on murine species using Cytarabine magnetic microspheres." International Journal of Public Health Science (IJPHS) 9, no. 3 (2020): 255. http://dx.doi.org/10.11591/ijphs.v9i3.20468.

Full text

Abstract:

Cytarabine magnetic microspheres were formulated and checked for their antileukemic potential. Leukemia was persuaded in the Wister strain of rat by intravenous injection of benzene. Blood was procured and various hematological parameters were noted and compared. Animals were divided into four groups, antileukemial potential was found to be maximum in case of magnetic microspheres of Cytarabine. The study shows the Antileukemic potential of Cytarabine magnetic microspheres.

APA, Harvard, Vancouver, ISO, and other styles

2

Satinder, Kakar, Jain Anurekha, and Singh Ramandeep. "In vivo study on murine species using Cytarabine magnetic microspheres." International Journal of Public Health Science (IJPHS) 9, no. 3 (2020): 255~258. https://doi.org/10.11591/ijphs.v9i3.20468.

Full text

Abstract:

Cytarabine magnetic microspheres were formulated and checked for their antileukemic potential. Leukemia was persuaded in the Wister strain of rat by intravenous injection of benzene. Blood was procured and various hematological parameters were noted and compared. Animals were divided into four groups, antileukemial potential was found to be maximum in case of magnetic microspheres of Cytarabine. The study shows the Antileukemic potential of Cytarabine magnetic microspheres.

APA, Harvard, Vancouver, ISO, and other styles

3

Mantadakis, Elpis, and Maria Kalmanti. "New Antileukemic Agents." Pediatric Hematology and Oncology 20, no. 3 (2003): 173–85. http://dx.doi.org/10.1080/08880010390158928.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Mantadakis, Elpis, and Maria Kalmanti. "New Antileukemic Agents." Pediatric Hematology and Oncology 20, no. 3 (2003): 173–85. http://dx.doi.org/10.1080/713842282.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Schmetzer, Helga, Friedhelm R. Schuster, Raymund Buhmann, et al. "Immunotherapy of Acute MYELOID LEUKEMIA: ANTI-LEUKEMIC EFFECTS by Unprimed or Primed, Selected or Unselected Effector T-CELLS." Blood 114, no. 22 (2009): 5122. http://dx.doi.org/10.1182/blood.v114.22.5122.5122.

Full text

Abstract:

Abstract Abstract 5122 T-cells are the most important mediators of antileukemic reactions after allogeneic stemcelltransplantation (SCT) or donorlymphocyte-infusions (DLI) in patients (pts) with myeloid leukemias (AML,MDS), although relapses occur. Presentation of leukemic antigens (LAA) is improved by conversion of leukemic cells to leukemia derived DC (DCleu). Our hypothesis is, that myeloid blasts convert in vivo spontaneously to DCleu and prime CTL; moreover DCleu can be generated ex vivo from blasts and be used to prime T-cells enabling the generation of leukemia-specific CTL. Therefore (

APA, Harvard, Vancouver, ISO, and other styles

6

Sanchez-Martin, Marta, Alberto Ambesi-Impiombato, Yue Qin, et al. "Synergistic antileukemic therapies inNOTCH1-induced T-ALL." Proceedings of the National Academy of Sciences 114, no. 8 (2017): 2006–11. http://dx.doi.org/10.1073/pnas.1611831114.

Full text

Abstract:

TheNotch1gene is a major oncogenic driver and therapeutic target in T-cell acute lymphoblastic leukemia (T-ALL). However, inhibition of NOTCH signaling with γ-secretase inhibitors (GSIs) has shown limited antileukemic activity in clinical trials. Here we performed an expression-based virtual screening to identify highly active antileukemic drugs that synergize with NOTCH1 inhibition in T-ALL. Among these, withaferin A demonstrated the strongest cytotoxic and GSI-synergistic antileukemic effects in vitro and in vivo. Mechanistically, network perturbation analyses showed eIF2A-phosphorylation–me

APA, Harvard, Vancouver, ISO, and other styles

7

Altman, Jessica K., Amy Szilard, Bruce W. Konicek, et al. "Inhibition of Mnk kinase activity by cercosporamide and suppressive effects on acute myeloid leukemia precursors." Blood 121, no. 18 (2013): 3675–81. http://dx.doi.org/10.1182/blood-2013-01-477216.

Full text

Abstract:

Key Points The Mnk inhibitor cercosporamide suppresses human leukemic progenitors and exhibits antileukemic effects in a xenograft mouse model. Cercosporamide enhances the antileukemic effects of cytarabine in vitro and in vivo.

APA, Harvard, Vancouver, ISO, and other styles

8

Ranganathan, Parvathi, Xueyan Yu, Ramasamy Santhanam, et al. "Decitabine priming enhances the antileukemic effects of exportin 1 (XPO1) selective inhibitor selinexor in acute myeloid leukemia." Blood 125, no. 17 (2015): 2689–92. http://dx.doi.org/10.1182/blood-2014-10-607648.

Full text

Abstract:

Key Points Decitabine priming increases antileukemic effects of selinexor in AML in vitro and in vivo. Decitabine priming allows for decreasing the dose of selinexor in patients, thus increasing tolerability without affecting antileukemic activity.

APA, Harvard, Vancouver, ISO, and other styles

9

Dervieux, Thierry, Timothy L. Brenner, Yuen Y. Hon, et al. "De novo purine synthesis inhibition and antileukemic effects of mercaptopurine alone or in combination with methotrexate in vivo." Blood 100, no. 4 (2002): 1240–47. http://dx.doi.org/10.1182/blood-2002-02-0495.

Full text

Abstract:

Methotrexate (MTX) and mercaptopurine (MP) are widely used antileukemic agents that inhibit de novo purine synthesis (DNPS) as a mechanism of their antileukemic effects. To elucidate pharmacodynamic differences among children with acute lymphoblastic leukemia (ALL), DNPS was measured in leukemic blasts from newly diagnosed patients before and after therapy with these agents. Patients were randomized to receive low-dose MTX (LDMTX: 6 oral doses of 30 mg/m2) or high-dose MTX (HDMTX: intravenous 1 g/m2) followed by intravenous MP; or intravenous MP alone (1 g/m2), as initial therapy. At diagnosis

APA, Harvard, Vancouver, ISO, and other styles

10

Mikhailovna Donnik, Irina. "Bovine Anti-leukemic Measures for Improving Live-Stock Farms in Belgorod and Kemerovo Regions of Russia." Bioscience Biotechnology Research Communications 14, no. 4 (2021): 1548–90. http://dx.doi.org/10.21786/bbrc/14.4.33.

Full text

Abstract:

Bovine leukemia remains one of the most urgent viral diseases in veterinary medicine, and potentially dangerous for humans. The strategy of combating it is aimed at improving the existing measures and full recovery of agricultural enterprises. The quality of animal products is a priority in the field of food safety. The aim of the research was to develop effective antileukemic measures for the improvement of livestock farms in the Belgorod and Kemerovo regions. The proposed antileukemic measures are to increase the frequency of serological studies from 6-th months to the 2-3th months among ani

APA, Harvard, Vancouver, ISO, and other styles

11

Houda, Sbayou. "IN VITRO ANTILEUKEMIC ACTIVITY OF EUPHORBIA ECHINUS EXTRACT." Biotechnologia Acta 15, no. 6 (2022): 70–74. http://dx.doi.org/10.15407/biotech15.06.070.

Full text

Abstract:

Aim. Cancer continues to pose a serious threat to human health. Euphorbia plants are rich in phenolics, aromatic esters, steroids and several bioactive compounds. Studies have shown the presence of a large number of bioactive compounds in E. echinus including flavonoids, phenolics, and proanthocyanins. Method. There it was investigated cytotoxic effects of E. echinus methanolic extract on K562, HL60, Ishikawa, Raji and SH-SY5Y cells. Results. The E. echinus extract was found to be highly cytotoxic against HL60 and K562 (79.78 and 76.44% cytotoxicity, respectively). DNA fragmentation was exclus

APA, Harvard, Vancouver, ISO, and other styles

12

Leufven, Eva, and Øystein Bruserud. "Immunosuppression and Immunotargeted Therapy in Acute Myeloid Leukemia - The Potential Use of Checkpoint Inhibitors in Combination with Other Treatments." Current Medicinal Chemistry 26, no. 28 (2019): 5244–61. http://dx.doi.org/10.2174/0929867326666190325095853.

Full text

Abstract:

Introduction: Immunotherapy by using checkpoint inhibitors is now tried in the treatment of several malignancies, including Acute Myeloid Leukemia (AML). The treatment is tried both as monotherapy and as a part of combined therapy. Methods: Relevant publications were identified through literature searches in the PubMed database. We searched for (i) original articles describing the results from clinical studies of checkpoint inhibition; (ii) published articles describing the immunocompromised status of AML patients; and (iii) published studies of antileukemic immune reactivity and immunotherapy

APA, Harvard, Vancouver, ISO, and other styles

13

&NA;. "R115777 shows 'promising antileukemic activity'." Inpharma Weekly &NA;, no. 1294 (2001): 11. http://dx.doi.org/10.2165/00128413-200112940-00024.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Sukari, M. A., R. Utami, B. K. Neoh, et al. "Antileukemic Properties of Spermacoce Species." Asian Journal of Chemistry 25, no. 8 (2013): 4595–98. http://dx.doi.org/10.14233/ajchem.2013.14218a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Ochs, Judith, and Raymond K. Mulhern. "Late Effects of Antileukemic Treatment." Pediatric Clinics of North America 35, no. 4 (1988): 815–33. http://dx.doi.org/10.1016/s0031-3955(16)36511-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

BORMAN, STU. "Conjugate drug shows antileukemic activity." Chemical & Engineering News 73, no. 8 (1995): 33. http://dx.doi.org/10.1021/cen-v073n008.p033.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Nasim, Shama, and Peter A. Crooks. "Antileukemic activity of aminoparthenolide analogs." Bioorganic & Medicinal Chemistry Letters 18, no. 14 (2008): 3870–73. http://dx.doi.org/10.1016/j.bmcl.2008.06.050.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Mikkelsen, Torben S., Alex Sparreboom, Cheng Cheng, et al. "Shortening Infusion Time for High-Dose Methotrexate Alters Antileukemic Effects: A Randomized Prospective Clinical Trial." Journal of Clinical Oncology 29, no. 13 (2011): 1771–78. http://dx.doi.org/10.1200/jco.2010.32.5340.

Full text

Abstract:

Purpose To determine whether shortening the infusion duration of high-dose methotrexate (HDMTX; 1 g/m2) affects the in vivo accumulation of active methotrexate polyglutamates (MTXPG1-7) in leukemia cells and whether this differs among major acute lymphoblastic leukemia (ALL) subtypes. Methods From June 2000 through October 2007, 356 children with ALL were randomly assigned to receive initial single-agent treatment with HDMTX (1 g/m2) as either a 24-hour infusion or a 4-hour infusion at two pediatric hospitals in the United States. The primary outcome measures were the accumulation of MTXPG1-7

APA, Harvard, Vancouver, ISO, and other styles

19

TURAK, Berfin Tugba. "PHYTOCHEMICAL CONSTITUENTS AND ANTILEUKEMIC EFFECTS OF JUNIPERUS OXYCEDRUS EXTRACT." Biotechnologia Acta 15, no. 5 (2022): 64–70. http://dx.doi.org/10.15407/biotech15.05.064.

Full text

Abstract:

Aim: Many genetic and environmental factors can be effective in the process of cancerization. Preventing the progression of leukemia may be possible by controlling the pathways involving mechanisms such as apoptosis and autophagy. When the literature is examined, there are studies showing the effects of various types of juniper on various cancer cell lines, including human chronic myeloid leukemia cells, but the signal pathways in which they act are not fully known. In this study, the anticancer effects of Juniperus oxycedrus extract on K-562 human chronic myeloid leukemia cells were investiga

APA, Harvard, Vancouver, ISO, and other styles

20

da Silva Castro, Elaine, Livia Azeredo Alves Antunes, Jonathas Felipe Revoredo Lobo, et al. "Antileukemic Properties of Sesquiterpene Lactones: A Systematic Review." Anti-Cancer Agents in Medicinal Chemistry 18, no. 3 (2018): 323–34. http://dx.doi.org/10.2174/1871520617666170918130126.

Full text

Abstract:

This review summarizes the reported molecular mechanisms underlying the antileukemic property of Sesquiterpene Lactones (SLs). This systematic review was registered in the PROSPERO database and conducted following the PRISMA Statements. The MeSH terms, Sesquiterpenes, Lactones and Leukemia were used in four databases (Pubmed, Web of Science, Scopus and Bireme). There were 281 studies selected, but after exclusions, due to replication (n = 172) or not following PECOS criteria (n = 24), 148 studies remained. Of the 148 articles, only 22 were submitted to quality assessment and were scored in hig

APA, Harvard, Vancouver, ISO, and other styles

21

Sanchez-Martin, Marta, Alberto Ambesi-Impiombato, Luyao Xu, et al. "Synergistic Targeting of Protein Translation and Inhibition of NOTCH Signaling in T-ALL." Blood 126, no. 23 (2015): 3719. http://dx.doi.org/10.1182/blood.v126.23.3719.3719.

Full text

Abstract:

Abstract Oncogenic NOTCH signaling is a major driver of T-cell transformation in T-cell acute lymphoblastic leukemia (T-ALL). However, clinical studies testing the efficacy of NOTCH1 inactivation with γ-secretase inhibitors (GSIs) have shown limited antileukemic activity for these drugs as single agents. Here we used an expression-based virtual screening approach and network perturbation analyses to identify and functionally characterize new highly active antileukemic drugs synergistic with NOTCH1 inhibition in T-ALL. Gene expression profiling studies have shown a prominent gene expression sig

APA, Harvard, Vancouver, ISO, and other styles

22

Acharya, S. N., K. Acharya, S. Paul, and S. K. Basu. "Antioxidant and antileukemic properties of selected fenugreek (Trigonella foenum-graecum L.) genotypes grown in western Canada." Canadian Journal of Plant Science 91, no. 1 (2011): 99–105. http://dx.doi.org/10.4141/cjps10025.

Full text

Abstract:

Acharya, S. N., Acharya, K., Paul, S. and Basu S. K. 2011. Antioxidant and antileukemic properties of selected fenugreek (Trigonella foenum-graecum L.) genotypes grown in western Canada. Can. J. Plant Sci. 91: 99–105. Fenugreek (Trigonella foenum-graecum L.) is an annual forage legume known to have a number of important medicinal properties such as being anti-diabetic and hyperchloesterolaemic among others. In this study we have investigated the anti-oxidant and antileukemic properties of five fenugreek genotypes (L3068, L3375, Tristar, PI143504 and Amber) grown in western Canada for their pot

APA, Harvard, Vancouver, ISO, and other styles

23

Ricciardi, M. R., R. Licchetta, S. Mirabilii, et al. "Preclinical Antileukemia Activity of Tramesan: A Newly Identified Bioactive Fungal Metabolite." Oxidative Medicine and Cellular Longevity 2017 (2017): 1–8. http://dx.doi.org/10.1155/2017/5061639.

Full text

Abstract:

Despite improvements that occurred in the last decades in the acute myeloid leukemia (AML) treatment, clinical results are still unsatisfactory. More effective therapies are required, and innovative approaches are ongoing, including the discovery of novel antileukemia natural compounds. Several studies have described the activity of extracts from mushrooms which produce compounds that exhibited immunological and antitumor activities. The latter has been demonstrated to be promoted in vitro by mushroom polysaccharides via induction of apoptosis. However, the antileukemia activity of these compo

APA, Harvard, Vancouver, ISO, and other styles

24

Tran Quang, Christine, Benedetta Zaniboni, Romain Humeau та ін. "Preclinical efficacy of humanized, non–FcγR-binding anti-CD3 antibodies in T-cell acute lymphoblastic leukemia". Blood 136, № 11 (2020): 1298–302. http://dx.doi.org/10.1182/blood.2019003801.

Full text

Abstract:

Abstract T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy that accounts for ∼20% of ALL cases. Intensive chemotherapy regimens result in cure rates &gt;85% in children and &lt;50% in adults, warranting a search of novel therapeutic strategies. Although immune-based therapies have tremendously improved the treatment of B-ALL and other B-cell malignancies, they are not yet available for T-ALL. We report here that humanized, non–Fcγ receptor (FcγR)–binding monoclonal antibodies (mAbs) to CD3 have antileukemic properties in xenograft (PDX) models of CD3+ T-ALL, resul

APA, Harvard, Vancouver, ISO, and other styles

25

Benjamin, Reuben, Asim Khwaja, Nalini Singh та ін. "Continuous delivery of human type I interferons (α/β) has significant activity against acute myeloid leukemia cells in vitro and in a xenograft model". Blood 109, № 3 (2006): 1244–47. http://dx.doi.org/10.1182/blood-2006-02-002915.

Full text

Abstract:

Abstract In this study, we focused primarily on the antileukemic activity of interferon-β (IFN-β) in a murine xenograft model of acute myeloid leukemia (AML). Bolus administration of recombinant IFN-β via the subcutaneous or intravenous route failed to show efficacy in mice injected with AML cells despite achieving peak plasma IFN-β levels of more than 200 IU/mL. In contrast, stable expression of IFN-β following adeno-associated virus (AAV) vector–mediated gene transfer resulted in significant antileukemic activity against primary AML cells derived from patients with poor prognostic markers. A

APA, Harvard, Vancouver, ISO, and other styles

26

Ohnuma, T., and J. F. Holland. "Homoharringtonine as a new antileukemic agent." Journal of Clinical Oncology 3, no. 5 (1985): 604–6. http://dx.doi.org/10.1200/jco.1985.3.5.604.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Ney, Paul A. "The antileukemic activity of Δ12-PGJ3". Blood 118, № 26 (2011): 6728–29. http://dx.doi.org/10.1182/blood-2011-10-385328.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Nasim, Shama, ShanShan Pei, Fred K. Hagen, Craig T. Jordan, and Peter A. Crooks. "Melampomagnolide B: A new antileukemic sesquiterpene." Bioorganic & Medicinal Chemistry 19, no. 4 (2011): 1515–19. http://dx.doi.org/10.1016/j.bmc.2010.12.045.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Bransová, Janette, Julius Brtko, Michal Uher, and Ladislav Novotný. "Antileukemic activity of 4-pyranone derivatives." International Journal of Biochemistry & Cell Biology 27, no. 7 (1995): 701–6. http://dx.doi.org/10.1016/1357-2725(95)00031-j.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

CIRRINCIONE, G., A. ALMERICO, G. DATTOLO, et al. "3-Triazenoindoles. Synthesis and antileukemic activity." European Journal of Medicinal Chemistry 29, no. 11 (1994): 889–91. http://dx.doi.org/10.1016/0223-5234(94)90112-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Antoniolli, Giorgio, Keli Lima, João Agostinho Machado-Neto, Carmen Silvia Passos Lima, and Fernando Coelho. "SYNTHETIC QUINAZOLINONES AS NEW ANTILEUKEMIC AGENTS." Hematology, Transfusion and Cell Therapy 47 (May 2025): 103763. https://doi.org/10.1016/j.htct.2025.103763.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Hubscher, Elizabeth, Slaven Sikirica, Timothy J. Bell, et al. "Patterns of Undertreatment Among Patients with Acute Myeloid Leukemia (AML) Not Receiving Standard Intensive Induction Chemotherapy." Blood 136, Supplement 1 (2020): 18–19. http://dx.doi.org/10.1182/blood-2020-137425.

Full text

Abstract:

Introduction: AML, a life-threatening malignancy, is most common in older adults. Due to the advanced age and heterogeneity of the patient population, selecting appropriate therapy presents a challenge for clinicians. Studies have demonstrated that regardless of age, patients with AML benefit from receiving antileukemic therapy, including standard intensive induction and non-intensive chemotherapy, and current guidelines recommend that treatment selection be based on individual patient and disease characteristics, e.g., performance status (PS), cytogenetic risk, comorbidity burden, and age. Ne

APA, Harvard, Vancouver, ISO, and other styles

33

Unterfrauner, Marianne, Hazal Aslan Rejeski, Anne Hartz, et al. "Granulocyte-Macrophage-Colony-Stimulating-Factor Combined with Prostaglandin E1 Create Dendritic Cells of Leukemic Origin from AML Patients’ Whole Blood and Whole Bone Marrow That Mediate Antileukemic Processes after Mixed Lymphocyte Culture." International Journal of Molecular Sciences 24, no. 24 (2023): 17436. http://dx.doi.org/10.3390/ijms242417436.

Full text

Abstract:

Although several (chemotherapeutic) protocols to treat acute myeloid leukemia (AML) are available, high rates of relapses in successfully treated patients occur. Strategies to stabilize remissions are greatly needed. The combination of the (clinically approved) immune-modulatory compounds Granulocyte-Macrophage-Colony-Stimulating-Factor (GM-CSF) and Prostaglandine E1 (PGE-1) (Kit-M) converts myeloid blasts into dendritic cells of leukemic origin (DCleu). After stimulation with DCleu ex vivo, leukemia-specific antileukemic immune cells are activated. Therefore, Kit-M treatment may be an attract

APA, Harvard, Vancouver, ISO, and other styles

34

Gutierrez, Alejandro, Alex Kentsis, Li Pan, et al. "Phenothiazines Induce Apoptosis in T-Cell Acute Lymphoblastic Leukemia by Activating the Phosphatase Activity of the PP2A Tumor Suppressor." Blood 120, no. 21 (2012): 3558. http://dx.doi.org/10.1182/blood.v120.21.3558.3558.

Full text

Abstract:

Abstract Abstract 3558 Despite the use of intensive and toxic treatment regimens, T-cell acute lymphoblastic leukemia (T-ALL) remains fatal in 25% of children and 60% of adults, highlighting the need for novel therapeutic strategies. We performed two complementary small molecule screens to identify novel T-ALL therapeutic agents: i) an in vivo zebrafish screen for small molecules toxic to MYC-overexpressing thymocytes, and ii) an in vitro screen for drugs that synergize with NOTCH inhibitors in human T-ALL cell lines. Hits common to both screens included perphenazine, an FDA-approved phenothia

APA, Harvard, Vancouver, ISO, and other styles

35

Wolff, Nicholas C., Darren R. Veach, William P. Tong, William G. Bornmann, Bayard Clarkson, and Robert L. Ilaria. "PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia." Blood 105, no. 10 (2005): 3995–4003. http://dx.doi.org/10.1182/blood-2004-09-3534.

Full text

Abstract:

AbstractImatinib mesylate is highly effective in newly diagnosed chronic myeloid leukemia (CML), but BCR/ABL (breakpoint cluster region/abelson murine leukemia)–positive progenitors persist in most patients with CML treated with imatinib mesylate, indicating the need for novel therapeutic approaches. In this study, we have used the murine CML-like myeloproliferative disorder as a platform to characterize the pharmacokinetic, signal transduction, and antileukemic properties of PD166326, one of the most potent members of the pyridopyrimidine class of protein tyrosine kinase inhibitors. In mice w

APA, Harvard, Vancouver, ISO, and other styles

36

Nikolova-Mladenova, Boryana, Rositsa Mihaylova, Mariyana Atanasova, Zvetanka Zhivkova, and Irini Doytchinova. "Salicylaldehyde Benzoylhydrazones with Anticancer Activity and Selectivity: Design, Synthesis, and In Vitro Evaluation." Molecules 30, no. 5 (2025): 1015. https://doi.org/10.3390/molecules30051015.

Full text

Abstract:

Dimethoxy derivatives of salicylaldehyde benzoylhydrazone containing a methoxy group on both aromatic rings were designed and synthesized. The compounds were obtained in high yields, and their structures were confirmed by elemental analysis and various spectral techniques. In vitro evaluation of dimethoxy hydrazones demonstrated potent activity against the leukemic cell lines at low micro- and nanomolar concentrations. Remarkably, two dimethoxy analogs showed exceptional antileukemic selectivity, with no toxicity observed in normal human embryonic kidney HEK-293 cells. In silico modeling ident

APA, Harvard, Vancouver, ISO, and other styles

37

Lutz, Mathias, Andrea Worschech, Miriam Alb, et al. "Boost and loss of immune responses against tumor-associated antigens in the course of pregnancy as a model for allogeneic immunotherapy." Blood 125, no. 2 (2015): 261–72. http://dx.doi.org/10.1182/blood-2014-09-601302.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Torelli, Giovanni F., Nadia Peragine, Paola Mariglia, and Robin Foà. "The antileukemic potential of natural killer cells." Immunotherapy 8, no. 4 (2016): 425–34. http://dx.doi.org/10.2217/imt-2015-0009.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Balis, Frank M., and David G. Poplack. "Central Nervous System Pharmacology of Antileukemic Drugs." Journal of Pediatric Hematology/Oncology 11, no. 1 (1989): 74–86. http://dx.doi.org/10.1097/00043426-198921000-00017.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Grem, J. L., B. D. Cheson, S. A. King, B. Leyland-Jones, and M. Suffness. "Cephalotaxine Esters: Antileukemic Advance or Therapeutic Failure?" JNCI Journal of the National Cancer Institute 80, no. 14 (1988): 1095–103. http://dx.doi.org/10.1093/jnci/80.14.1095.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Chow, Sue, Masazumi Nagai, Suqin He, et al. "Antileukemic Effects of the Novel Agent Elesclomol." Blood 114, no. 22 (2009): 2736. http://dx.doi.org/10.1182/blood.v114.22.2736.2736.

Full text

Abstract:

Abstract Abstract 2736 Poster Board II-712 Elesclomol (N-malonyl-bis (N′-methyl-N′-thiobenzoyl hydrazide)) is an investigational first-in-class oxidative stress inducer that triggers apoptosis in cancer cells (Kirshner et al., Mol Cancer Ther 2008;7:2319–27). In the clinic, elesclomol is well tolerated in humans and showed activity in combination with paclitaxel in patients with refractory solid tumors (Berkenblit et al., Clin Cancer Res 2007;13:584–90). The aims of the current study are to examine the activity of elesclomol against a range of AML cell lines, including primary patient blast cu

APA, Harvard, Vancouver, ISO, and other styles

42

Kishi, Shinji, Cheng Cheng, Deborah French, et al. "Ancestry and pharmacogenetics of antileukemic drug toxicity." Blood 109, no. 10 (2007): 4151–57. http://dx.doi.org/10.1182/blood-2006-10-054528.

Full text

Abstract:

Abstract Treatment-related toxicity in acute lymphoblastic leukemia (ALL) can not only be life threatening but may also affect relapse risk. In 240 patients, we determined whether toxicities were related to 16 polymorphisms in genes linked to the pharmacodynamics of ALL chemotherapy, adjusting for age, race (self-reported or via ancestry-informative markers), sex, and disease risk group (lower- vs higher-risk therapy). Toxicities (gastrointestinal, infectious, hepatic, and neurologic) were assessed in each treatment phase. During the induction phase, when drugs subject to the steroid/cytochrom

APA, Harvard, Vancouver, ISO, and other styles

43

Gologan, Radu, Gabriela Constantinescu, Daniela Georgescu, et al. "Hypolipemiant besides antileukemic effect of imatinib mesylate." Leukemia Research 33, no. 9 (2009): 1285–87. http://dx.doi.org/10.1016/j.leukres.2009.02.024.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Akbay, Pınar, Jürg Gertsch, Ihsan Çalıs, Jörg Heilmann, Oliver Zerbe, and Otto Sticher. "Novel Antileukemic Sterol Glycosides from Ajuga salicifolia." Helvetica Chimica Acta 85, no. 7 (2002): 1930. http://dx.doi.org/10.1002/1522-2675(200207)85:7<1930::aid-hlca1930>3.0.co;2-c.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Foltankova, Veronika, Eva Matejkova, Milan Bartos, et al. "Molecular Identification of Individual T Cell Clones Specific for Graft- Versus-Leukemia Reaction." Blood 112, no. 11 (2008): 1249. http://dx.doi.org/10.1182/blood.v112.11.1249.1249.

Full text

Abstract:

Abstract Graft-verus-leukemia (GVL) effect in hematopoietic stem cell transplantation (HSCT) is usually complicated by the alloreactivity of donor T cells which leads to acute graft-versus-host (GVH) disease. GVL and GVH reactions are proved to be mediated by different T cell clones. The objective of this study was to identify and characterize T cells clones with specific antileukemia activity without mediating GVHD. We have performed primary mixed leukocyte reaction (MLR) using patient non-leukemic irradiated peripherial blood mononuclear cells (PBMC) as stimulators and donor PBMC as responde

APA, Harvard, Vancouver, ISO, and other styles

46

Bin Shahari, Muhammad Syafiq, Ahmad Junaid, Edward R. T. Tiekink, and Anton V. Dolzhenko. "6-Aryl-4-cycloamino-1,3,5-triazine-2-amines: synthesis, antileukemic activity, and 3D-QSAR modelling." RSC Advances 14, no. 12 (2024): 8264–82. http://dx.doi.org/10.1039/d3ra08091a.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Mohammadian Gol, Tahereh, Miso Kim, Ralph Sinn, et al. "CRISPR-Cas9-Based Gene Knockout of Immune Checkpoints in Expanded NK Cells." International Journal of Molecular Sciences 24, no. 22 (2023): 16065. http://dx.doi.org/10.3390/ijms242216065.

Full text

Abstract:

Natural killer (NK) cell immunotherapy has emerged as a novel treatment modality for various cancer types, including leukemia. The modulation of inhibitory signaling pathways in T cells and NK cells has been the subject of extensive investigation in both preclinical and clinical settings in recent years. Nonetheless, further research is imperative to optimize antileukemic activities, especially regarding NK-cell-based immunotherapies. The central scientific question of this study pertains to the potential for boosting cytotoxicity in expanded and activated NK cells through the inhibition of in

APA, Harvard, Vancouver, ISO, and other styles

48

Kim, Fred S. C., James T. Rutka, Mark Bernstein, Lothar Resch, Ellen Warner, and Dominic Pantalony. "Intradural granulocytic sarcoma presenting as a lumbar radiculopathy." Journal of Neurosurgery 72, no. 4 (1990): 663–67. http://dx.doi.org/10.3171/jns.1990.72.4.0663.

Full text

Abstract:

✓ Granulocytic sarcoma usually occurs in the setting of leukemia and myeloproliferative disorders. Rarely, it can occur in isolation at various anatomical sites without hematological evidence of leukemia. The unique case of an elderly man presenting with right L2–3 radiculopathy is described. Intradural granulocytic sarcoma of the L-2 and L-3 nerve roots with extradural extension was found at surgery and he was treated with incomplete resection and antileukemic chemotherapy. Local recurrence at 3 months was treated with irradiation. Granulocytic sarcoma is frequently misdiagnosed and invariabl

APA, Harvard, Vancouver, ISO, and other styles

49

Vigón, Lorena, Alejandro Luna, Miguel Galán, et al. "Identification of Immunological Parameters as Predictive Biomarkers of Relapse in Patients with Chronic Myeloid Leukemia on Treatment-Free Remission." Journal of Clinical Medicine 10, no. 1 (2020): 42. http://dx.doi.org/10.3390/jcm10010042.

Full text

Abstract:

BCR-ABL is an aberrant tyrosine kinase responsible for chronic myeloid leukemia (CML). Tyrosine kinase inhibitors (TKIs) induce a potent antileukemic response mostly based on the inhibition of BCR-ABL, but they also increase the activity of Natural Killer (NK) and CD8+ T cells. After several years, patients may interrupt treatment due to sustained, deep molecular response. By unknown reasons, half of the patients relapse during treatment interruption, whereas others maintain a potent control of the residual leukemic cells for several years. In this study, several immunological parameters relat

APA, Harvard, Vancouver, ISO, and other styles

50

Gaidano, Valentina, Mohammad Houshmand, Nicoletta Vitale, et al. "The Synergism between DHODH Inhibitors and Dipyridamole Leads to Metabolic Lethality in Acute Myeloid Leukemia." Cancers 13, no. 5 (2021): 1003. http://dx.doi.org/10.3390/cancers13051003.

Full text

Abstract:

Dihydroorotate Dehydrogenase (DHODH) is a key enzyme of the de novo pyrimidine biosynthesis, whose inhibition can induce differentiation and apoptosis in acute myeloid leukemia (AML). DHODH inhibitors had shown promising in vitro and in vivo activity on solid tumors, but their effectiveness was not confirmed in clinical trials, probably because cancer cells exploited the pyrimidine salvage pathway to survive. Here, we investigated the antileukemic activity of MEDS433, the DHODH inhibitor developed by our group, against AML. Learning from previous failures, we mimicked human conditions (perform

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!